SK bioscience and Sanofi have announced positive results from the Phase II study of their 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202). The vaccine demonstrated positive safety and immunogenicity data in infants. The companies plan to start Phase III trials in the first half of 2024.
The Phase II clinical trial evaluated the safety and immunogenicity of GBP410 in infants aged 42 to 89 days and toddlers aged 12 to 15 months. The study enrolled a total of 852 participants across multiple countries. Results showed that GBP410 had comparable immunogenicity to the control vaccine and a well-tolerated safety profile, with no serious adverse events related to the vaccine.
GBP410 is a pneumococcal conjugate vaccine developed by SK bioscience and Sanofi. It combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae, providing effective protection against pneumococcal infections such as pneumonia and invasive pneumococcal disease. With its inclusion of 21 serotypes, it offers broader serotype